Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-11-01

Summary

This study is a prospective, umbrella-design, Phase II clinical trial. Eligible participants with advanced or metastatic gastric cancer who are treatment-nave for advanced-stage systemic therapy will undergo biomarker profiling (HER2, CLDN18.2, and PD-L1) via next-generation sequencing (NGS) or immunohistochemistry (IHC). Participants will be stratified into distinct molecular subtypes and assigned subtype-specific therapeutic regimens. The primary objectives are to assess treatment efficacy (e.g., objective response rate) and safety profiles across molecularly defined cohorts.

• Phase: PHASE2

Details

• Lead Sponsor: China Medical University, China
• Treatments: apatinib; Capecitabine; Oxaliplatin; S 1 (combination); SHR-1701; Trastuzumab; zolbetuximab